Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour

Giuseppe Badalamenti, Dagrada, Fumagalli, Baldi, Morosi, Paolo Casali, Toss, Cominetti, Festinese, Salvatore Provenzano, Gronchi, Dei Tos, Badalamenti, Stacchiotti, Negri, Pennacchioli, Monica Tortoreto, Dei Tos, Nadia Zaffaroni, GrignaniPilotti, Spagnuolo

Risultato della ricerca: Articlepeer review

39 Citazioni (Scopus)


Background To explore the activity of pazopanib in solitary fibrous tumour (SFT). Patients and methods In a preclinical study, we compared the activity of pazopanib, sorafenib, sunitinib, regorafenib, axitinib and bevacizumab in a dedifferentiated-SFT (DSFT) xenotransplanted into Severe Combined Immunodeficiency (SCID) mice. Antiangiogenics were administered at their reported optimal doses when mean tumour volume (TV) was 80 mm3. Drug activity was assessed as TV inhibition percentage (TVI%). From May 2012, six consecutive patients with advanced SFT received pazopanib, on a national name-based programme. In one case sunitinib was administered after pazopanib failure. Results In the xenograft model, pazopanib showed the lowest antitumour activity (21%TVI), while regorafenib was the most active (95%TVI). Sorafenib, bevacizumab, sunitinib were markedly active (78/70/65%TVI). Axitinib was marginally active (51%TVI). In the retrospective case-series, three patients carried malignant-SFT (MSFT), three DSFT. Best Response Evaluation Criteria in Solid Tumour (RECIST) responses were: three stable disease (SD), all MSFT, three progressive disease (PD), all DSFT, corresponding to one partial response (PR), two SD, three PD by Choi criteria. Median-progression-free survival was 3 months (range 1-15). In one patient, sunitinib was started after pazopanib failure, with a response. Conclusions In dedifferentiated-SFT xenograft pazopanib induced a marginal antitumour activity, while regorafenib appeared the most active and promising agent. When administered in patients, pazopanib showed a modest activity in terms of tumour growth stabilisation, observed only in non-dedifferentiated cases.
Lingua originaleEnglish
pagine (da-a)3021-3028
Numero di pagine8
RivistaEuropean Journal of Cancer
Stato di pubblicazionePublished - 2014

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2730???
  • ???subjectarea.asjc.1300.1306???


Entra nei temi di ricerca di 'Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour'. Insieme formano una fingerprint unica.

Cita questo